FRAXA’s mission is to discover specific treatments and ultimately a cure for Fragile X syndrome, aiming to transition practical treatment into current medical practice quickly. They prioritize projects with clear, practical applications, emphasizing results sharing in a timely manner. By funding research grants and fellowships globally and partnering with biomedical and pharmaceutical companies, FRAXA bridges the gap between research discoveries and treatments, benefiting individuals affected by Fragile X and potentially those with autism, Alzheimer's, and other brain disorders.
FRAXA’s grant and fellowship programs are designed to support the discovery of new and improved treatments and ultimately a cure for Fragile X syndrome. Emphasizing disease-modifying therapeutics that stem from an understanding of Fragile X disease mechanisms, FRAXA allocates $50,000 yearly for up to two years through their fellowship program. The foundation prioritizes research likely to overcome current "bottlenecks" in developing treatments, evolving their funding priorities based on the state of research and emerging challenges. Initially focusing on basic research and the integration of neuroscientists into Fragile X studies, FRAXA now directs resources towards translational research and preclinical validation, given the progress made in understanding the disease and developing potential therapeutics. The shift reflects their strategic adaptation to the changing landscape of Fragile X research, aiming to accelerate the pace of discovery and clinical application of treatments.